Drug Profile
Research programme: hepatitis virus gene therapy - Immune Response
Alternative Names: Hepatitis virus gene therapy research programme - Immune ResponseLatest Information Update: 01 May 2007
Price :
$50
*
At a glance
- Originator Immune Response Corporation
- Developer Orchestra Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic hepatitis
Most Recent Events
- 01 May 2007 Discontinued - Preclinical for Chronic hepatitis in USA (IV-injection)
- 31 Dec 2001 This programme is still in active development
- 20 Sep 1999 Preclinical development for Chronic hepatitis in USA (IV-injection)